AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1988575
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy (tamoxifen and chemotherapy)
Trial: 6997516
Drug: Single 2-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 2-g dose of metronidazole
Trial: 7039761
Drug: Single 1-g
RxNorm normalized name: bacitracin
DrugBank: Bacitracin (DB00626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single 1-g dose of metronidazole
Trial: 7039761
Drug: Retreatment with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retreatment with a single 2-g dose of metronidazole after initial failure
Trial: 29692183
Drug: Moxibustion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion treatment (Group A) from days 1 to 14
Trial: 29692183
Drug: Moxibustion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion treatment (Group B) from days 15 to 28
Trial: 23758233
Drug: Inhaled racemic
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled racemic adrenaline
Trial: 15622223
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A injection followed by surgical deactivation of migraine trigger sites
Trial: 8568113
Drug: Omeprazole treatment
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole treatment (n = 8)
Trial: 2187310
Drug: Combination regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination regimen with 0.064% betametason dipropionate ointment (Diprosis) for 1 week before dithranol therapy (B + CSV-therapy)
Trial: 2187310
Drug: Conventional dithranol
RxNorm normalized name: Zithranol
DrugBank: Anthralin (DB11157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dithranol therapy (CSV-therapy)
Trial: 758758
Drug: Intravenous acebutolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acebutolol
Trial: 30876438
Drug: Low-intensity arm
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity arm training (same quantity, frequency and treatment time as the intervention group)
Trial: 26900895
Drug: 1-session treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-session treatment (OST)
Trial: 26900895
Drug: 1-session treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-session treatment (OST) and educational support (EST)
Trial: 22241639
Drug: Pentoxifylline (PTF)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTF) 400 mg twice a day, n=46
Trial: 22241639
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual therapy), n=45
Trial: 15175958
Drug: Protocol treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol treatment (n = 27)
Trial: 15175958
Drug: Non-protocol treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-protocol treatment (n = 14)
Trial: 15175958
Drug: Cisplatin chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin chemotherapy (cumulative dose >/= 400 mg/m2)
Trial: 11182191
Drug: Trimetazidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (40 mg bolus followed by 60 mg/day intravenously for 48 h)
Trial: 9638347
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg testosterone buciclate
Trial: 9638347
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg testosterone buciclate
Trial: 8074262
Drug: Turbuhaler (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turbuhaler (0.5 mg terbutaline x 2)
Trial: 8074262
Drug: CFC inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFC inhaler (0.25 mg terbutaline x 4)
Trial: 31027110
Drug: Moderate-intensity continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-intensity continuous aerobic exercise (MICAE) 3 times weekly for 12 weeks
Trial: 23779062
Drug: IncobotulinumtoxinA (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IncobotulinumtoxinA (both doses)
Trial: 18849173
Drug: Glimepiride (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (1 mg)/Metformin (500 mg)
Trial: 18849173
Drug: Glibenclamide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (5 mg)/Metformin (500 mg)
Trial: 11093989
Drug: Dexamethasone 5
RxNorm normalized name: dexamethasone 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 5 mg (D5)
Trial: 11093989
Drug: Dexamethasone 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 2.5 mg (D2.5)
Trial: 11093989
Drug: Dexamethasone 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 1.25 mg (D1.25)
Trial: 8684648
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine analgesia
Trial: 26932142
Drug: Preoperative duloxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative duloxetine treatment
Trial: 23592231
Drug: Computerized cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized cognitive behavioral therapy (cCBT)
Trial: 14699463
Drug: Adequate antibiotic
RxNorm normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adequate antibiotic treatment
Trial: 14699463
Drug: Inadequate antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inadequate antibiotic treatment
Trial: 11156542
Drug: UVA‐1 cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVA‐1 cold light treatment
Trial: 11156542
Drug: UVA‐1 cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVA‐1 cold light treatment vs Placebo
Trial: 9683005
Drug: Ketamine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.3 mg/kg i.v.
Trial: 28569454
Drug: Amoxicillin +
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin + Clavulanic acid (2 g/day for 6 days)
Trial: 28569454
Drug: Antibiotic +
RxNorm normalized name: Antibiotic + Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic + Probiotic (Bifidobacterium longum + lactoferrin)
Trial: 28569454
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic therapy (Control group)
Trial: 9349846
Drug: Twice-yearly mebendazole
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-yearly mebendazole (500 mg)
Trial: 9349846
Drug: Thrice-yearly mebendazole
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thrice-yearly mebendazole (500 mg)
Trial: 6102838
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no beta-blocker therapy)
Trial: 3709031
Drug: Cetamolol (46
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetamolol (46 +/- 21 mg/day)
Trial: 29393233
Drug: Supplemental oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen or asthma medications
Trial: 25790770
Drug: 4.5-mm diameter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5-mm diameter implant (test)
Trial: 25790770
Drug: 3.75-mm diameter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75-mm diameter implant (control)
Trial: 24037900
Drug: All IPL
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All IPL doses
Trial: 23276521
Drug: Adjuvant 5‐fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant 5‐fluorouracil (5‐FU)‐based chemotherapy
Trial: 10566571
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/d for 12 weeks (n = 194)
Trial: 10566571
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg/d for 12 weeks (n = 193)
Trial: 10566571
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/d for 12 weeks
Trial: 10566571
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg/d for 12 weeks
Trial: 9987507
Drug: Dexamethasone 4
RxNorm normalized name: dexamethasone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 4 mg/day
Trial: 30701815
Drug: Rectal suppositories
RxNorm normalized name: Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal suppositories containing IFN‐α2b (1 million IU) and antioxidants (alpha‐tocopherol acetate and ascorbic acid) twice a day for 5 days
Trial: 30701815
Drug: Intranasal gel
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal gel formulation containing IFN‐α2b (36 000 IU/1 g) and antioxidants 3 times a day in addition to rectal suppositories
Trial: 30701815
Drug: Umifenovir (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umifenovir (reference drug) at a dose of 200 mg 4 times a day for 5 days
Trial: 30701815
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rectal and topical dosage forms of IFN‐α2b with antioxidants
Trial: 20505654
Drug: Steroids +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids + Cyclophosphamide
Trial: 16126373
Drug: Clotiapine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotiapine (40 mg)
Trial: 16126373
Drug: Chlorpromazine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (100 mg)
Trial: 14728113
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of SSRIs with aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)
Trial: 10997885
Drug: Hydroxyurea (HU)
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (HU) therapy in PV patients
Trial: 10997885
Drug: Hydroxyurea (HU)
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (HU) therapy in ET patients
Trial: 10997885
Drug: Phlebotomy therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phlebotomy therapy in PV patients
Trial: 10997885
Drug: Combined groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined groups of PV and ET without myelosuppressive treatment
Trial: 31533799
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care intervention (including cognitive-behavioral therapy, care management, and psychotropic medication consultation)
Trial: 22130792
Drug: Prednisone 30
RxNorm normalized name: prednisone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 30 mg/d (group A)
Trial: 22130792
Drug: Sodium perchlorate
RxNorm normalized name: sodium perchlorate
DrugBank: Sodium perchlorate (DB16608)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium perchlorate 500 mg twice daily (group B)
Trial: 20639801
Drug: Anatomically shaped
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anatomically shaped permanent expander implant McGhan Style 150
Trial: 20639801
Drug: Round permanent
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Round permanent expander implant Siltex Becker 25
Trial: 10883415
Drug: Triazolam (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.25 mg) administered orally during the follicular phase
Trial: 10883415
Drug: Triazolam (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.25 mg) administered orally during the ovulatory phase
Trial: 10883415
Drug: Triazolam (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.25 mg) administered orally during the luteal phase
Trial: 10883415
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green (0.5 mg/kg) administered as an i.v. bolus during the follicular phase
Trial: 10883415
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green (0.5 mg/kg) administered as an i.v. bolus during the ovulatory phase
Trial: 10883415
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green (0.5 mg/kg) administered as an i.v. bolus during the luteal phase
Trial: 9187068
Drug: G‐CSF (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (10 microg per kilogram of body weight per day subcutaneously)
Trial: 1586602
Drug: Continuous low
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous low dose infusion of recombinant interleukin-2 (rIL-2) at doses of 0.18 x 10(6) IU, 0.6 x 10(6) IU, 1.8 x 10(6) IU, 3 x 10(6) IU, 6 x 10(6) IU, and 9 x 10(6) IU per m2 per 24 h.
Trial: 1586602
Drug: Continuous low
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous low dose infusion of recombinant interleukin-2 (rIL-2) at a dose of 1.8 x 10(6) IU m-2 24 h-1.
Trial: 20074020
Drug: Toremifene (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene (20 mg/d)
Trial: 18198271
Drug: Antidepressant use
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant use during follow-up
Trial: 12519797
Drug: Systematic reviews
RxNorm normalized name: Integrase Inhibitors, antiinfectives for systematic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic reviews of herbal medicines
Trial: 10958089
Drug: ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine 0.2% followed by ropivacaine 0.1% + 2 microg x ml(‐1) fentanyl infusion
Trial: 10958089
Drug: bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.25% followed by bupivacaine 0.125% + 2 microg x ml(‐1) fentanyl infusion
Trial: 1579324
Drug: E2 (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 (75 mg) alone
Trial: 1579324
Drug: E2 (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 (75 mg) with testosterone (100 mg)
Trial: 26475356
Drug: Q3W group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q3W group (capecitabine 1,000 mg/m² twice daily on days 1-14 and oxaliplatin 130 mg/m² on day 1 every 21 days)
Trial: 26475356
Drug: Q2W group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q2W group (capecitabine 2,000 mg/m² twice daily on days 1-7 and oxaliplatin 85 mg/m² on day 1 every 14 days)
Trial: 18328059
Drug: 1% pimecrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% pimecrolimus cream applied to the right hemi-face, twice daily for 4 weeks
Trial: 18328059
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied to the left hemi-face, twice daily for 4 weeks
Trial: 19143948
Drug: Midazolam 0.5
RxNorm normalized name: midazolam 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.5 mg x kg(‐1) oral 30 min before surgery (max 15 mg)
Trial: 11376505
Drug: Tramadol in
RxNorm normalized name: tramadol Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol in continuous infusion (dose 12 mg/h)
Trial: 11376505
Drug: Ketorolac in
RxNorm normalized name: ketorolac Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac in continuous infusion
Trial: 11376505
Drug: Morphine in
RxNorm normalized name: morphine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine in repeated boluses
Trial: 9391249
Drug: Loxiglumide (LOX)
RxNorm normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide (LOX) infusion (66 mumol/kg/h for 10 min followed by 22 mumol/kg/h)
Trial: 9391249
Drug: Loxiglumide (LOX)
RxNorm normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide (LOX) infusion
Trial: 8203853
Drug: Ciprofloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (400 mg every 8 h)
Trial: 8203853
Drug: Imipenem (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem (1,000 mg every 8 h)
Trial: 12885750
Drug: L-DOPS
RxNorm normalized name: L-DOPS
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-DOPS
Trial: 9876215
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day donepezil
Trial: 1787894
Drug: Heparan sulfate
RxNorm normalized name: heparan sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparan sulfate (200 mg/die, one 100 mg tablet twice a day) for 60 days
Trial: 11002380
Drug: 0.3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 g/day of n-3 PUFA for 8 weeks
Trial: 11002380
Drug: 0.6 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 g/day of n-3 PUFA for 8 weeks
Trial: 11002380
Drug: 0.9 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 g/day of n-3 PUFA for 8 weeks
Trial: 11002380
Drug: 0 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g/day of n-3 PUFA for 8 weeks (placebo)
Trial: 9496777
Drug: Acute attack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute attack drugs (sumatriptan, ergot derivatives, NSAIDs)
Trial: 9496777
Drug: Oestrogen supplementation
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen supplementation with percutaneous or transdermal oestradiol (100 microg patches)
Trial: 9496777
Drug: Antioestrogen agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioestrogen agents (danazol, tamoxifen)
Trial: 22228235
Drug: Human rotavirus
RxNorm normalized name: Live attenuated human Rotavirus RIX4414 strain Ag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human rotavirus vaccine
Trial: 2527532
Drug: Cilazapril 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 1.25 mg
Trial: 2527532
Drug: Cilazapril intravenous
RxNorm normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril intravenous 5 micrograms kg‐1
Trial: 2527532
Drug: Cilazapril intravenous
RxNorm normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril intravenous 20 micrograms kg‐1
Trial: 2527532
Drug: Cilazapril repeated
RxNorm normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril repeated administration for 8 days
Trial: 29617758
Drug: Headgear (HG)
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Hydro-Tussin HG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Headgear (HG) treatment
Trial: 19501822
Drug: Withania somnifera
RxNorm normalized name: WITHANIA SOMNIFERA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withania somnifera treatment
Trial: 18539917
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (targeting glycated hemoglobin level below 6.0%)
Trial: 18539917
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (targeting glycated hemoglobin level from 7.0 to 7.9%)
Trial: 16038713
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg plus acetylsalicylic acid 75 mg
Trial: 16038713
Drug: Extended-release dipyridamole
RxNorm normalized name: ASPIRIN 25 mg / DIPYRIDAMOLE 200 mg ORAL CAPSULE, EXTENDED RELEASE [ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release dipyridamole 200 mg plus acetylsalicylic acid 25 mg
Trial: 10090427
Drug: Loading-dose metrifonate
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading-dose metrifonate (100 mg or 150 mg for 2 weeks, then 50 mg for 4 weeks)
Trial: 10090427
Drug: No-loading-dose metrifonate
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-loading-dose metrifonate (50 mg for 6 weeks)
Trial: 10090427
Drug: Loading-dose metrifonate
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading-dose metrifonate
Trial: 10090427
Drug: No-loading-dose metrifonate
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-loading-dose metrifonate
Trial: 8539322
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg) and (100 mg)